Spheroid– tag –
-
Celvivo Secures $6.6M to Propel Advanced 3D Cell Culture Platform, Appoints New CEO for Commercial Scale-Up
Dealroom News Denmark Overview Danish biotech Celvivo has raised $6.6 million from a mix of existing and new investors, earmarked for the accelerated commercial expansion of its ClinoStar 3D cell culture platform. This platform, which ge... -
ABM Unveils Spheroid & Organoid Medium Portfolio to Revolutionize 3D Culture Workflows for Drug Discovery and Disease Modeling
ABM (via Facebook) International Overview ABM has launched a new Spheroid & Organoid Medium portfolio designed to robustly support reproducible and scalable 3D culture workflows for drug discovery and disease modeling. This new produ... -
REPROCELL Enhances 3D Cell Culture Product Portfolio with Alvetex® & EZSPHERE™ to Advance Drug Discovery Translational Research
REPROCELL Japan Overview REPROCELL is fortifying its diverse 3D cell culture product lines, including Alvetex® 3D Cell Culture Systems and the Alvetex® Advanced Tissue Bioengineering System, to provide biologically relevant, reproducible... -
Bioneer Unveils BioSPHEER™: A 3D Cancer Model Revolutionizing Solid Tumor Drug Discovery
Bioneer Denmark Overview Bioneer has launched BioSPHEER™, an innovative in vitro 3D cancer platform designed to significantly enhance drug efficacy prediction for solid tumors. This platform generates high-fidelity tumor models by assemb... -
HTMP Biotechnology Unveils HTMP™ 192: A 192-Well High-Throughput 3D Cell Culture Platform Addressing Spheroid Loss During Media Exchange
HTMP Biotechnology USA Overview HTMP Biotechnology has launched its HTMP™ 192, an SBS/SLAS-compatible 192-well microwell platform designed to overcome a critical limitation in 3D cell culture: spheroid loss during media exchange. This pl... -
Heartseed Doses First Patient in Phase I/II EMERALD Study with iPSC-Derived Cardiomyocyte Spheroids HS-005 for Severe Heart Failure; Nikon CeLL innovation Provides Manufacturing Support
Heartseed Japan Overview Heartseed announced the successful dosing of the first patient in its Phase I/II EMERALD study for HS-005, an iPSC-derived cell therapy for severe heart failure. HS-005 consists of cardiomyocyte spheroids manufac... -
Advanced 3D Bioprinting Techniques Drive Progress in Organoid and Tissue Development for Regenerative Medicine and Drug Discovery
News-Medical.Net UK Overview This technical article highlights advancements in 3D bioprinting for creating sophisticated organoid and tissue models, emphasizing their potential for cell therapy, personalized diagnostics, and drug discove...
1